Direct thrombin inhibitors.
Di Nisio
Marcello
M
Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. m.dinisio@amc.uva.nl
Middeldorp
Saskia
S
Büller
Harry R
HR
D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000991:Antithrombins; D001120:Arginine / Q000031:analogs & derivatives; D001562:Benzimidazoles / Q000627:therapeutic use; D001777:Blood Coagulation / Q000502:physiology; D000069604:Dabigatran; D006331:Heart Diseases / Q000188:drug therapy* / Q000628:therapy; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D010875:Pipecolic Acids / Q000627:therapeutic use; D011355:Prodrugs / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000502:physiology; D013923:Thromboembolism / Q000517:prevention & control; D013927:Thrombosis / Q000188:drug therapy*; D020246:Venous Thrombosis / Q000188:drug therapy
D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D010875:Pipecolic Acids; D011355:Prodrugs; D011725:Pyridines; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; D013917:Thrombin; D000069604:Dabigatran; C031942:argatroban